Saint John’s Cancer Institute
  • Home
  • About Us
    • Saint John’s Cancer Institute
      • Banchik Family Library
      • Blog
      • Events
      • In The News
      • Patents & Innovations
      • Research Administration
      • Translational Research Departments
    • Saint John’s Health Center
      • Cancer Support Services
      • Cancer Support Team
      • Contact a Specialist
      • COVID-19 Information
      • Visit the Health Center Website
    • Saint John’s Health Center Foundation
      • Inspiring Stories from Our Foundation
      • Make a Donation
      • Philanthropy Sponsored Programs
      • Webinars
      • Your Healthy Dose Podcast
      • Visit the Foundation Website
  • Centers of Excellence
    • Brain Tumors & Neuroscience
    • Breast Surgery and Oncology
    • Endocrine Tumors and Disorders
    • Gastrointestinal and Hepatobiliary Tumors
    • Gynecologic Oncology
    • Head and Neck Oncology
    • Melanoma, Skin and Soft Tissue Tumors
    • Pathology
    • Thoracic Surgical Oncology
    • Translational Research Departments
    • Urology and Urologic Oncology
  • Clinical Trials
    • Active Clinical Trials
    • Clinical Trials FAQs
    • COVID-19 Research
  • Fellowship Programs
    • Fellowship Overview
      • Recent Alumni & Current Fellows
    • Breast Surgical Oncology Fellowship
    • Donald L. Morton Complex General Surgical Oncology Fellowship
    • Neurosurgery Fellowship
    • Translational Molecular Medicine Fellowship
    • Urologic Oncology and Robotics Fellowship
  • Contact Us
    • Directory & Phone Numbers
    • Maps & Directions to Saint John’s Health Center
  • Access Providence My Chart
  • Search
  • Donate to Life-saving Research

Solid Tumor Clinical Trials

Clinical Trials Solid Tumor Clinical Trials

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Subjects With Advanced Cancer

This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of a novel Fc-engineered IgG1 anti-CTLA-4 human monoclonal antibody (AGEN1181), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors. This study will also determine the RP2D of AGEN1181 monotherapy.

Learn more

Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

This is a phase 1b/2, open-label, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral AST-008 injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors.

Learn more

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

Diseases: cutaneous melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, renal cell carcinoma. Part B (Accruing now): up to 15 patients in each disease will be enrolled and evaluated for safety, immunogenicity, and antitumor activity of GEN-009. Patients will receive GEN-009 with PD-1 inhibitor at the approved dose and schedule.

Learn More

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Novel use of TKI cabozantinib to amplify activity of checkpoint inhibitor atezolizumab in multiple malignancies.

Learn More

⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Advanced or Metastatic Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck Selected to Receive Standard-of-Care Immunotherapy as Single Agent or in Combination.

Learn More

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab.

Learn More

I Want To:

Request an Appointment
Enter a Fellowship
Participate In A Clinical Trial
Donate Now
Careers

Connect With Us:

Locations Map
Contact Us
Main Facility Phone
310-315-6125
Providence Resource Line
888-432-5464

  • Facebook
  • LinkedIn
  • Twitter
  • Instagram
  • YouTube

About Saint John’s Cancer Institute

Saint John’s Cancer Institute is a renowned research facility dedicated to advanced therapeutics, translational science, and best practices. We support fellowships and clinical trials, collaborating with industry and academic partners worldwide.

Administrative Office & Research Center:
2200 Santa Monica Blvd.
Santa Monica, CA 90404
Cancer Clinic:
Providence Saint John’s Health Center
2121 Santa Monica Blvd.
Santa Monica, CA 90404

©2023 Saint John’s Cancer Institute. All Rights Reserved. Site Map